Intronic miR-3151 within BAALC drives leukemogenesis by deregulating the TP53 pathway

Science Signaling

Volumn 7, Issue 321, 2014, Pages

  Eisfeld, Ann Kathrin ^a   Schwind, Sebastian ^a   Patel, Ravi ^a   Huang, Xiaomeng ^a   Santhanam, Ramasamy ^a   Walker, Christopher J ^a   Markowitz, Joseph ^a   Hoag, Kevin W ^a   Jarvinen, Tiina M ^a   Leffel, Benjamin ^a   Perrotti, Danilo ^a   Carson III, William E ^a   Marcucci, Guido ^a   Bloomfield, Clara D ^a   De La Chapelle, Albert ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 3151; PROTEIN P53; TRANSCRIPTION FACTOR RUNX1; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; BAALC PROTEIN, HUMAN; BORONIC ACID DERIVATIVE; BORTEZOMIB; MESSENGER RNA; MIRN3151 MICRORNA, HUMAN; PYRAZINE DERIVATIVE; RUNX1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR PROTEIN;

3' UNTRANSLATED REGION; ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN AND ACUTE LEUKEMIA CYTOPLASMIC GENE; CANCER CELL CULTURE; CANCER GROWTH; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; GENE DISRUPTION; GENE LOCUS; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRON; LEUKEMIA CELL; LEUKEMOGENESIS; MALE; MELANOMA CELL; MIXED INFECTION; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; STIMULATION; TRANSACTIVATION; ANIMAL; BIOLOGY; CHEMISTRY; CHROMOSOME; CYTOGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MELANOMA; METABOLISM; MORTALITY; NONOBESE DIABETIC MOUSE; PHENOTYPE; SCID MOUSE; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CHROMOSOMES; COMPUTATIONAL BIOLOGY; CORE BINDING FACTOR ALPHA 2 SUBUNIT; CYTOGENETICS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INTRONS; LEUKEMIA, MYELOID, ACUTE; MALE; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; NEOPLASM PROTEINS; NF-KAPPA B; PHENOTYPE; PYRAZINES; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899095828     PISSN: 19450877     EISSN: 19379145     Source Type: Journal    
DOI: 10.1126/scisignal.2004762     Document Type: Article

References (30)

1. A. Burnett, M. Wetzler, B. Löwenberg, Therapeutic advances in acute myeloid leukemia. J. Clin. Oncol. 29, 487-494 (2011).
2. E. Estey, H. Döhner, Acute myeloid leukaemia. Lancet 368, 1894-1907 (2006).
3. S. Fröhling, R. F. Schlenk, S. Kayser, M. Morhardt, A. Benner, K. Döhner, H. Döhner; German-Austrian AML Study Group, Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: Results from AMLSG trial AML HD98-B. Blood 108, 3280-3288 (2006).
4. K. Mrózek, G. Marcucci, P. Paschka, S. P. Whitman, C. D. Bloomfield, Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: Are we ready for a prognostically prioritized molecular classification? Blood 109, 431-448 (2007).
5. G. Marcucci, T. Haferlach, H. Döhner, Molecular genetics of adult acute myeloid leukemia: Prognostic and therapeutic implications. J. Clin. Oncol. 29, 475-486 (2011).
6. S. M. Tanner, J. L. Austin, G. Leone, L. J. Rush, C. Plass, K. Heinonen, K. Mrózek, H. Sill, S. Knuutila, J. E. Kolitz, K. J. Archer, M. A. Caligiuri, C. D. Bloomfield, A. de la Chapelle, BAALC, the human member of a novel mammalian neuroectoderm gene lineage, is implicated in hematopoiesis and acute leukemia. Proc. Natl. Acad. Sci. U.S.A. 98, 13901-13906 (2001).
7. C. D. Baldus, P. Martus, T. Burmeister, S. Schwartz, N. Gökbuget, C. D. Bloomfield, D. Hoelzer, E. Thiel, W. K. Hofmann, Low ERG and BAALC expression identifies a new subgroup of adult acute T-lymphoblastic leukemia with a highly favorable outcome. J. Clin. Oncol. 25, 3739-3745 (2007).
8. A. Kühnl, N. Gökbuget, A. Stroux, T. Burmeister, M. Neumann, S. Heesch, T. Haferlach, D. Hoelzer, W. K. Hofmann, E. Thiel, C. D. Baldus, High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 115, 3737-3744 (2010).
9. D. Schrama, G. Keller, R. Houben, C. G. Ziegler, C. S. Vetter-Kauczok, S. Ugurel, J. C. Becker, BRAFV600E mutations in malignant melanoma are associated with increased expressions of BAALC. J. Carcinog. 7, 1 (2008).
10. N. P. Agaram, M. P. Laquaglia, B. Ustun, T. Guo, G. C. Wong, N. D. Socci, R. G. Maki, R. P. DeMatteo, P. Besmer, C. R. Antonescu, Molecular characterization of pediatric gastrointestinal stromal tumors. Clin. Cancer Res. 14, 3204-3215 (2008).
11. C. D. Baldus, S. M. Tanner, A. S. Ruppert, S. P. Whitman, K. J. Archer, G. Marcucci, M. A. Caligiuri, A. J. Carroll, J.W. Vardiman, B. L. Powell, S. L. Allen, J. O.Moore, R. A. Larson, J. E. Kolitz, A. de la Chapelle, C. D. Bloomfield, BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: A Cancer and Leukemia Group B study. Blood 102, 1613-1618 (2003).
12. M. Bienz, M. Ludwig, E. O. Leibundgut, B. U. Mueller, D. Ratschiller, M. Solenthaler, M. F. Fey, T. Pabst, Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin. Cancer Res. 11, 1416-1424 (2005).
13. M. A. Eid, M. Attia, S. Abdou, S. F. El-Shazly, L. Elahwal, W. Farrag, L. Mahmoud, BAALC and ERG expression in acute myeloid leukemia with normal karyotype: Impact on prognosis. Int. J. Lab. Hematol. 32, 197-205 (2010).
14. S. Schwind, G. Marcucci, K. Maharry, M. D. Radmacher, K. Mrózek, K. B. Holland, D. Margeson, H. Becker, S. P. Whitman, Y. Z. Wu, K. H. Metzeler, B. L. Powell, J. E. Kolitz, T. H. Carter, J. O. Moore, M.R. Baer, A. J. Carroll, M. A. Caligiuri, R. A. Larson, C. D. Bloomfield, BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. Blood 116, 5660-5669 (2010).
15. M. Heuser, T. Berg, F. Kuchenbauer, C. K. Lai, G. Park, S. Fung, G. Lin, M. Leung, J. Krauter, A. Ganser, R. K. Humphries, Functional role of BAALC in leukemogenesis. Leukemia 26, 532-536 (2012).
16. F. Lovat, N. Valeri, C. M. Croce, MicroRNAs in the pathogenesis of cancer. Semin. Oncol. 38, 724-733 (2011).
17. A. Rodriguez, S. Griffiths-Jones, J. L. Ashurst, A. Bradley, Identification of mammalian microRNA host genes and transcription units. Genome Res. 14, 1902-1910 (2004).
18. S. Griffiths-Jones, Annotating noncoding RNA genes. Annu. Rev. Genomics Hum. Genet 8, 279-298 (2007).
19. M. S. Stark, S. Tyagi, D. J. Nancarrow, G. M. Boyle, A. L. Cook, D. C. Whiteman, P. G. Parsons, C. Schmidt, R. A. Sturm, N. K. Hayward, Characterization of the melanoma miRNAome by deep sequencing. PLOS One 5, e9685 (2010).
20. D. Schotte, A. Akbari, F. Moqadam, E. A. M. Lange-Turenhout, C. Chen, W. F. van Ijcken, R. Pieters, M. L. den Boer, Discovery of new microRNAs by small RNAome deep sequencing in childhood acute lymphoblastic leukemia. Leukemia 25, 1389-1399 (2011).
21. A. K. Eisfeld, G. Marcucci, K. Maharry, S. Schwind, M. D. Radmacher, D. Nicolet, H. Becker, K. Mrózek, S. P. Whitman, K. H. Metzeler, J. H. Mendler, Y. Z. Wu, S. Liyanarachchi, R. Patel, M. R. Baer, B. L. Powell, T. H. Carter, J. O. Moore, J. E. Kolitz, M. Wetzler, M. A. Caligiuri, R. A. Larson, S. M. Tanner, A. de la Chapelle, C. D. Bloomfield, miR-3151 interplays with its host gene BAALC and independently impacts on outcome of patients with cytogenetically normal acute myeloid leukemia. Blood 120, 249-258 (2012).
22. A. J. Levine, p53, the cellular gatekeeper for growth and division. Cell 8, 323-331 (1997).
23. E. Yonish-Rouach, D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, M. Oren, Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352, 345-347 (1991).
24. B. Vogelstein, K. W. Kinzler, p53 function and dysfunction. Cell 70, 523-526 (1992).
25. P. Ranganathan, X. Yu, C. Na, R. Santhanam, S. Shacham, M. Kauffman, A. Walker, R. Klisovic, W. Blum, M. Caligiuri, C. M. Croce, G. Marcucci, R. Garzon, Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia. Blood 120, 1765-1773 (2012).
26. S. Liu, L. C. Wu, J. Pang, R. Santhanam, S. Schwind, Y. Z. Wu, C. J. Hickey, J. Yu, H. Becker, K. Maharry, M. D. Radmacher, C. Li, S. P. Whitman, A. Mishra, N. Stauffer, A. M. Eiring, R. Briesewitz, R. A. Baiocci, K. K. Chan, P. Paschka, M. A. Caligiuri, J. C. Byrd, C. M. Croce, C. D. Bloomfiled, D. Perrotti, R. Garzon, G. Marcucci, Sp1/NFkB/HDAC/ miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 17, 333-347 (2010).
27. W. Blum, S. Schwind, S. S. Tarighat, S. Geyer, A. K. Eisfeld, S. Whitman, A. Walker, R. Klisovic, J. C. Byrd, R. Santhanam, H. Wang, J. P. Curfman, S. M. Devine, S. Jacob, C. Garr, C. Kefauver, D. Perrotti, K. K. Chan, C. D. Bloomfield, M. A. Caligiuri, M. R. Grever, R. Garzon, G. Marcucci, Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia. Blood 119, 6025-6031 (2012).
28. F. Oszolak, L. L. Poling, Z. Wang, H. Liu, X. S. Liu, G. H. Roeder, X. Zhang, J. S. Song, D. E. Fisher, Chromatin structure analyses identify miRNA promoters. Genes Dev. 22, 3172-3183 (2008).
29. A. Mas Monteys, R. M. Spengler, J.Wan, L. Tecedor, K. A. Lennox, Y. Xing, B. L. Davidson, Structure and activity of putative intronic miRNA promoters. RNA 16, 495-505 (2010).
30. A. K. Eisfeld, G. Marcucci, S. Liyanarachchi, K. Döhner, S. Schwind, K. Maharry, B. Leffel, H. Döhner, M. D. Radmacher, C. D. Bloomfield, S. M. Tanner, A. de la Chapelle, Heritable polymorphism predisposes to high BAALC expression in acute myeloid leukemia. Proc. Natl. Acad. Sci. U.S.A. 109, 6668-6673 (2012).